Global Regulatory Monitor
Regulatory News, Week 4 · 2026/6

Finding inadequate assignment of data integrity responsibilities and inadequate change control records together at a hospital manufacturing site suggests the document system built on the quality system is not being operated consistently. Findings on the GMP committee procedure and on reviewing the deviation handling procedure show the management level of the internal quality organisation becoming the issue at inspection.

Inadequate process water records and cleaning verification for weighing utensils appearing together at a finished product site reconfirms that equipment management procedures and the execution of cleaning validation are core inspection items. The finding on data integrity role assignment reflects a consistent expectation that the roles and responsibilities of the dedicated unit be documented.

That MFDS made storage condition monitoring and cleaning verification the core findings at a post-approval inspection of an overseas active ingredient site suggests these two are the priority items when maintaining qualification of an API supplier. Those managing overseas API supply chains should review supplier temperature and humidity monitoring records and cleaning validation reports on a regular basis.

The same equipment cleaning standard being breached again, and treated as a second offence, signals that MFDS judges the effectiveness of corrective action strictly through escalating penalties. Missing entries on an equipment cleaning history card attract an aggravated penalty once they recur after a first finding, so the system for completing and reviewing those cards needs re-examining.

A GMP inspection of an API site passing with no findings is a positive confirmation for maintaining qualification of that supplier. Finished product manufacturers using this supplier should update the inspection outcome in their supplier qualification records.

A laboratory finding goes to the core of quality control work, covering execution of analytical methods, test records and instrument management. The detail needs to be read from the attached inspection result, but laboratory procedures being current and the integrity of test data are the first things worth checking.

Growth promotion testing not following the standard, graded major, appearing together with inadequate environmental monitoring criteria at a sterile radiopharmaceutical facility points to weakness in the sterility assurance system for that process. Cyclotron and radioisotope drug sites should give priority to bringing the media fill procedure and the environmental monitoring standard up to date.

A late report of controlled substance handling records escalating to an aggravated second offence shows that timeliness of reporting into the national narcotics information system can attract cumulative penalties on repeat breach. Firms manufacturing or handling controlled substances should tighten how they check that entry and reporting procedures are carried out.

A post-approval inspection of a Japanese finished product site closing without findings confirms that the supplier's GMP compliance is being maintained. To keep marketing authorisations for imported finished products in place, the supplier's post-approval inspection outcome should be refreshed and reflected in the qualification records.

A Spanish finished product site coming through a post-approval inspection with no findings is a case where EU GMP practice and the domestic MFDS standard line up. Even for EU-based suppliers, the independent MFDS post-approval inspection outcome should be reflected in supplier qualification records.

An excess of N-nitroso-meglumine in a telmisartan preparation leading to a precautionary recall reconfirms that nitrosamines arising from an excipient, meglumine here, also fall within the scope of ICH M7 control. Sites making telmisartan and meglumine containing preparations should review their nitrosamine risk assessment, particularly for N-nitroso-meglumine, and the suitability of the test method.

N-nitroso-meglumine exceeding the permitted limit across several products of a DPP-4 inhibitor and metformin combination shows that control of nitrosamines arising from metformin material and process remains a live industry issue. Sites making metformin combination products should revisit the N-nitroso-meglumine risk assessment by material and the adequacy of the release test method.

A dissolution failure in stability testing means the product moved outside specification while in distribution, and for a narrow therapeutic index drug such as warfarin the effect on patient safety can be significant. Firms should check that they monitor stability results in real time and hold criteria and a procedure for deciding immediately whether market action is required when a result goes out of specification.

A concern about appearance arising from a container defect shows that container and packaging suitability testing can be a leading indicator of stability failure. For liquid preparations such as syrups, the suitability of the container and closure seal and the appearance check before release should be reviewed regularly.

Glass particulate in a liposome injection can cause direct harm to the patient, which is why FDA applied its highest recall class. Injectable sites should review how defects in the primary glass container are detected and whether their visual and automated particulate inspection arrangements are adequate.

A nitroso impurity exceeding an interim limit in an SNRI leading to a Class II recall shows nitrosamine control extending beyond particular therapeutic classes to amine-containing active ingredients generally. Firms making duloxetine and similar amine drugs should confirm that their nitrosamine risk assessment and control methods are current.

N-nitroso-duloxetine exceeding the interim limit at both the 30mg and 60mg strengths from the same manufacturer suggests a systematic control failure at process or material level. The site needs a root cause investigation and CAPA addressing the common process cause, not testing each strength in isolation.

A leak from the cooling system of packaging equipment contaminating product directly shows that a maintenance defect can produce harm at Class I level. OTC finished product sites should re-examine the inspection frequency for cooling systems on packaging equipment and their leak detection arrangements from a CGMP standpoint.

Microbial contamination in the alcohol sanitizing product itself shows that a sanitizing agent can become a contamination route into a sterile manufacturing environment. Firms should re-examine the microbial limit specification for alcohols and disinfectants used to sanitize the manufacturing environment and the testing done on receipt.

Dissolution falling below specification in long-term stability testing goes directly to loss of therapeutic effect and is therefore grounds for a Class II recall. Extended-release forms carry a risk that the dissolution profile drifts outside the criteria over the stability period, so the acceptance criterion at the 24-hour timepoint and the out-of-specification response procedure should be reviewed.

A dissolution failure at the ninth month for an extended-release antibiotic underlines the need to track the dissolution profile closely across the whole shelf life. Once such a result is confirmed, the speed of the decision on market action is what matters for patient safety and for the regulatory response.

Foreign matter confirmed through a product quality complaint in a sterile inhalation ampoule exposes weaknesses in the aseptic filling and sealing process and in the particulate inspection arrangements. For a dosage form such as an inhalation suspension, where coloured particulate is hard to see, the suitability of the particulate inspection methodology needs re-examining.

Microbial contamination confirmed in a non-sterile OTC nasal spray shows that non-sterile preparations applied to the nose are also held strictly to microbial limit control and contamination prevention. Sites making non-sterile liquids for nasal, oral or topical use should review the basis on which the microbial limit specification was set and their microbial control strategy.